A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel

Inclusion Criteria: * HIV-negative * Willing to participate and sign an informed consent * Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized to a study group that includes the possibility of being assigned to a placebo group. * Willing to use two forms of contraception during the study. * Willing to undergo pelvic examinations with colposcopy and photographic documentation according to the protocol throughout the study. * Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses. * Willing to abstain from using any vaginal product (other than the study product or placebo). * Willing to be sexually abstinent from randomization until completion of Day 7 evaluations. Exclusion Criteria: * Currently pregnant or breast-feeding. * Clinically detectable genital abnormality on the vulva, vaginal walls or cervix. * Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis or clinically diagnosed genital ulcer disease or active HSV-2 lesions. * Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization. * Symptomatic bacterial vaginosis and unwilling to undergo treatment. * Women who require treatment for tuberculosis (TB) within 21 days prior to randomization.